BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Puxitatug samrotecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Puxitatug samrotecan\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05123482-2375@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Puxitatug samrotecan: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Puxitatug samrotecan\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Partic
 ipants With Advanced/Metastatic Solid Malignancies\nEstimated primary comp
 letion: 29 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/puxitatug-samrotecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05123482
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044336-2375@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Puxitatug samrotecan: Phase 3 readout est. (NCT07044336)
DESCRIPTION:Puxitatug samrotecan\, phase 3\, Endometrial Cancer.\nStudy: Pu
 xitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected
  Endometrial Cancer (Bluestar-Endometrial01)\nEstimated primary completion
 : 15 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pu
 xitatug-samrotecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07044336
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162480-2375@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Puxitatug samrotecan: Phase 2 readout est. (NCT07162480)
DESCRIPTION:Puxitatug samrotecan\, phase 2.\nStudy: Phase II Trial of Puxit
 atug Samrotecan (AZD8205) in Advanced\, Recurrent or Metastatic (R/M) Aggr
 essive Adenoid Cystic Carcinoma Subtype I (ACC-I)\nEstimated primary compl
 etion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/puxitatug-samrotecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07162480
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
